194 related articles for article (PubMed ID: 26979218)
41. Carbon-based compounds emerging as sparkling diamonds for IBS treatment?
Chao CY; Holtmann GJ
Aliment Pharmacol Ther; 2012 Jan; 35(1):199-200; author reply 200-2. PubMed ID: 22150540
[No Abstract] [Full Text] [Related]
42. Editorial: colesevelam effects on faecal bile acids in IBS with diarrhoea - author's reply.
Camilleri M
Aliment Pharmacol Ther; 2015 Apr; 41(7):697. PubMed ID: 25736145
[No Abstract] [Full Text] [Related]
43. Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.
Marbury TC; Berg JK; Dove LS; Covington PS
J Clin Pharmacol; 2017 Nov; 57(11):1454-1459. PubMed ID: 28719721
[No Abstract] [Full Text] [Related]
44. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome.
Chang L; Lembo A; Sultan S
Gastroenterology; 2014 Nov; 147(5):1149-72.e2. PubMed ID: 25224525
[No Abstract] [Full Text] [Related]
45. New drug for women with irritable bowel syndrome.
Mayo Clin Health Lett; 2003 Dec; 21(12):4. PubMed ID: 14971349
[No Abstract] [Full Text] [Related]
46. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.
Weinberg DS; Smalley W; Heidelbaugh JJ; Sultan S;
Gastroenterology; 2014 Nov; 147(5):1146-8. PubMed ID: 25224526
[No Abstract] [Full Text] [Related]
47. LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.
Camilleri M
IDrugs; 2010 Dec; 13(12):921-8. PubMed ID: 21154152
[TBL] [Abstract][Full Text] [Related]
48. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome.
Vahedi H; Merat S; Momtahen S; Kazzazi AS; Ghaffari N; Olfati G; Malekzadeh R
Aliment Pharmacol Ther; 2008 Apr; 27(8):678-84. PubMed ID: 18248658
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Chang FY; Lu CL; Chen CY; Luo JC
J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
[TBL] [Abstract][Full Text] [Related]
50. Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.
Pasricha PJ
Gastroenterology; 2007 Jun; 132(7):2287-90. PubMed ID: 17570201
[No Abstract] [Full Text] [Related]
51. Experts revise guidelines for irritable bowel syndrome.
Harv Womens Health Watch; 2009 Mar; 16(7):6-7. PubMed ID: 19402238
[No Abstract] [Full Text] [Related]
52. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
Camilleri M
Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
[No Abstract] [Full Text] [Related]
53. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.
Camilleri M
Expert Opin Pharmacother; 2013 Jun; 14(9):1151-60. PubMed ID: 23621801
[TBL] [Abstract][Full Text] [Related]
54. [Irritable bowel syndrome].
Musch A
Med Monatsschr Pharm; 2006 Oct; 29(10):378-9. PubMed ID: 17058897
[No Abstract] [Full Text] [Related]
55. Irritable bowel syndrome. Don't forget amitriptyline.
Leeds JS; Leeds CM; Sanders DS
BMJ; 2009 Jan; 338():a3150. PubMed ID: 19126615
[No Abstract] [Full Text] [Related]
56. [Drug treatment for irritable bowel syndrome].
Hillilä M; Färkkilä M
Duodecim; 2004; 120(20):2453-8. PubMed ID: 15641514
[No Abstract] [Full Text] [Related]
57. Antibiotic may improve irritable bowel syndrome.
Mayo Clin Health Lett; 2007 Mar; 25(3):4. PubMed ID: 17396340
[No Abstract] [Full Text] [Related]
58. Existing and emerging therapies for irritable bowel syndrome.
Acosta RD; Cash BD
Expert Opin Emerg Drugs; 2011 Jun; 16(2):389-402. PubMed ID: 21438740
[TBL] [Abstract][Full Text] [Related]
59. Irritable bowel syndrome: focus on otilonium bromide.
Boeckxstaens G; Clavé P; Corazziari ES; Tack J
Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):131-7. PubMed ID: 24417261
[TBL] [Abstract][Full Text] [Related]
60. Targeting serotonin synthesis to treat irritable bowel syndrome.
Tack J; Janssen P; Wouters M; Boeckxstaens G
Gastroenterology; 2011 Aug; 141(2):420-2. PubMed ID: 21703266
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
